What antidepressant should be initiated in a patient with major depressive disorder after a suicide attempt by ingesting sodium tablets, once the overdose is stabilized?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Antidepressant Selection After Suicide Attempt in Major Depressive Disorder

Once the sodium overdose is medically stabilized, initiate a second-generation antidepressant (SSRI or SNRI) as first-line pharmacotherapy, avoiding tricyclic antidepressants entirely due to their high lethality in overdose. 1, 2

Critical Safety Principle: Avoid Tricyclic Antidepressants

  • Tricyclic antidepressants (TCAs) are absolutely contraindicated as first-line therapy in any patient with suicidal behavior because they carry the highest fatality rate in overdose among all antidepressant classes. 2, 3, 4
  • TCAs cause life-threatening cardiac arrhythmias, seizures, hypotension, and coma at toxic levels (>1,000 ng/mL), with major toxicity manifesting within 6 hours of overdose. 3, 4
  • Second-generation antidepressants have equivalent efficacy to TCAs but markedly lower toxicity in overdose, making them the only appropriate choice for patients with suicide risk. 1, 2

Recommended First-Line Medication Options

Select from the following second-generation antidepressants based on adverse-effect profile, cost, and patient preference—all have equivalent efficacy: 1, 5

SSRIs (Preferred for Most Patients)

  • Sertraline 50 mg once daily (increase to 100–200 mg as tolerated) 5
  • Escitalopram 10 mg once daily (increase to 20 mg as tolerated) 5
  • Citalopram 20 mg once daily (maximum 40 mg; 20 mg maximum if age >60 years due to QT prolongation risk) 5
  • Fluoxetine 20 mg once daily (increase to 40–80 mg as tolerated) 5

SNRIs (Consider for Comorbid Pain or Cognitive Symptoms)

  • Venlafaxine 37.5–75 mg once daily (titrate to 150–225 mg) 5
  • Duloxetine 30–60 mg once daily 5

Atypical Antidepressant (Lowest Sexual Dysfunction Risk)

  • Bupropion SR 150 mg once daily (increase to 150 mg twice daily after 3 days; maximum 400 mg/day) 5
  • Contraindicated if seizure disorder or eating disorder present 6

Intensive Early Monitoring Protocol (Weeks 1–4)

Suicide risk peaks during the first 1–2 months of antidepressant treatment; mandatory close follow-up is required: 6, 5

  • Week 1–2: In-person or telephone assessment for emergence of suicidal thoughts, plans, intent, agitation, irritability, or unusual behavioral changes 6, 5
  • Weeks 3–4: Weekly contact to assess response, adverse effects, and continued safety 5
  • Weeks 5–8: Bi-weekly visits until response is established 5

Response Assessment and Treatment Adjustment (Weeks 6–8)

  • If symptom reduction is <50% on validated scales (PHQ-9, HAM-D, MADRS), modify the treatment plan by: 6, 7
    • Dose escalation to maximum FDA-approved dose
    • Switching to a different second-generation antidepressant class
    • Augmentation with bupropion, buspirone, or cognitive-behavioral therapy 6, 7

Combination Therapy for Severe Depression

  • For severe major depressive disorder with high suicide risk, initiate combination therapy with both an SSRI/SNRI and cognitive-behavioral therapy (CBT) concurrently—this approach nearly doubles remission rates (57% vs 31% with medication alone). 6, 7

Treatment Duration to Prevent Recurrence

  • Continue antidepressant therapy for a minimum of 4–9 months after achieving remission for a first depressive episode. 1, 5
  • For recurrent depression (≥2 prior episodes), maintain treatment for at least 1 year or longer. 1, 6, 5

Common Pitfall to Avoid

  • Do not prescribe paroxetine as first-line therapy in this population—it has the highest rates of sexual dysfunction and anticholinergic effects among SSRIs, which increases non-adherence risk in vulnerable patients. 5
  • Never use TCAs (amitriptyline, nortriptyline, imipramine, doxepin) as initial treatment in patients with any history of suicidal behavior—their lethality in overdose makes them inappropriate regardless of prior treatment failures. 2, 3, 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Safety and Clinical Role of First‑Generation Antidepressants

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Managing tricyclic antidepressant overdose.

American family physician, 1992

Guideline

Pharmacologic Management of Depression

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnostic Criteria and Treatment Options for Major Depressive Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.